Home Newsfeeds Pioneer Bancorp Q2 EPS $0.25, Same YoY

Pioneer Bancorp Q2 EPS $0.25, Same YoY

Pioneer Bancorp (NASDAQ:PBFS) reported quarterly earnings of $0.25 per share. This is unchanged from the same period last year.

byHappy Mohamed

January 30, 2023

1 minute read

Pioneer Bancorp (NASDAQ:PBFS) reported quarterly earnings of $0.25 per share. This is unchanged from the same period last year.

BetMGM Launches Sports Betting App In Puerto Rico

By Shivani Kumaresan

June 8, 11:44 AM

Sports betting operator, BetMGM, owned by MGM Resorts International (NYSE: MGM) and Entain Plc (OTC: GMVHY), has launched its

GMVHY

Earnings

Casey’s General Stores’s Return On Capital Employed Insights

By Benzinga Insights

September 15, 10:04 AM

According to Benzinga Pro, during Q1, Casey's General Stores (NASDAQ:CASY) earned $152.93 million, a 155.84% increase from the preceding quarter. Casey's General Stores also posted a total of $4.46 billion in sales, a 28.79% increase since Q4.

CASY

AbbVie’s Immunogen Acquired Elahere Meets Primary Goal In Mid-Stage Study In Heavily Pretreated Ovarian Cancer Patients

By Vandana Singh

June 6, 1:02 PM

AbbVie announced Phase 2 PICCOLO trial results for Elahere in heavily pre-treated ovarian cancer patients. The trial achieved a 51.9% objective response rate.

ABBV

Travere Therapeutics Announces Licensing Agreement With Renalys Pharma To Develop And Commercialize Sparsentan In Japan, South Korea, Taiwan, And Southeast Asian Nations

By Benzinga Newsdesk

January 25, 5:40 PM

Travere Therapeutics, Inc., (NASDAQ:TVTX) announced that it has entered into an exclusive licensing agreement with Renalys Pharma, Inc., to bring sparsentan, a dual endothelin angiotensin receptor antagonist for the

TVTX

Pioneer Bancorp Q2 EPS $0.25, Same YoY

Related Posts

BetMGM Launches Sports Betting App In Puerto Rico

Casey’s General Stores’s Return On Capital Employed Insights

AbbVie’s Immunogen Acquired Elahere Meets Primary Goal In Mid-Stage Study In Heavily Pretreated Ovarian Cancer Patients

Travere Therapeutics Announces Licensing Agreement With Renalys Pharma To Develop And Commercialize Sparsentan In Japan, South Korea, Taiwan, And Southeast Asian Nations